wsmith@harrisonhayes.com 704 906 3402

Life science investment banking boutique

An investment bank uniquely committed to serving innovation driven biotechnology, pharmaceutical and healthcare companies
EXPLORE OUR PORTFOLIO

Since our launch in 2007, we have advised clients on more than $25 billion worth of deals for biotechnology, branded pharmaceutical, digital health, generic pharmaceutical, and life sciences companies.

WHAT SETS US APART

Harrison Hayes' distinct DNA

Healthcare Heritage

Founded in 1997, we have emerged as the country’s largest healthcare merchant bank. We stand apart because of our 100% focus on healthcare & life sciences.

Results

Harrison Hayes has completed 200+ investment banking engagements. Over 60% of our successful transactions have been cross-border engagements.

Expert Teams

Our team of 50+ professionals, with their backgrounds in banking, corporate finance, equity research, consulting and public accounting, brings 400+ years of collective experience.

WHAT SETS US APART

Transactions

Our Portfolio

Harrison Hayes’ suite of offerings assist clients by providing world class analysis and advice on target technologies, research tools, human capital, companies, and markets. Our professionals are dedicated to providing actionable solutions to the most dominant issues our clients face.

Our Portfolio

We’re dedicated to building future life sciences champions.

OUR PORTFOLIO
Harrison Hayes’ suite of offerings assist clients by providing world-class analysis and advice on target technologies, research tools, human capital, companies, and markets. Our team of professionals are dedicated to providing actionable solutions to the most dominant issues our clients face.
Harrison Hayes Represented

BMS in the Identification and Securitization of a Strategic Alliance with Uniqure

Harrison Hayes Represented

CASI Pharma (China-U.S.) in their acquisition of 29 Generic Drug Candidates from Sandoz

Harrison Hayes Represented

Celgene in the Identification and Acquisition of Quanticel Pharmaceuticals

Harrison Hayes Represented

Forest Labs in the Identification and Licensing Transaction for U.S. Rights to Nycomed’s PDE-4 Inhibitor Daxas

Harrison Hayes Represented

Morphosys in the Identification and Acquisition of Lanthio Pharma

OUR CAPABILITIES

Services & Sectors

Pharmaceuticals and Biotechnology
Diagnostics and Life Sciences
Medical Device
Digital Health
Life Science Investors
Pharmaceuticals and Biotechnology
Harrison Hayes supports large, mid-size, and small pharma and biotech companies with expert-driven insights to navigate the intersection of scientific, clinical, and business strategy.
READ MORE
Diagnostics and Life Sciences
Harrison Hayes supports companies across a broad range of diagnostics and research tools to achieve and sustain growth. We focus on creating tailored strategies to support companies in the diagnostics and research tools space.
READ MORE
Medical Device
Harrison Hayes helps medical device companies successfully think beyond traditional approaches and maximize opportunity in new ventures, whether that is portfolio growth through acquisition or product planning in new markets.
READ MORE
Digital Health
Harrison Hayes has helped clients adapt to new value-based care (VBC) initiatives from government agencies, navigate the increasingly consolidated provider landscape, and enter new markets.
READ MORE
Life Science Investors
Harrison Hayes brings deep healthcare subject matter expertise, data-driven insights, quantitative rigor, and fast-paced and responsive client service to all our acquisition and partnering work.
READ MORE

Our knowledge at your service

Learn more about our expertise

Contact us

You’re just a message away from your business opportunity.

What sets us apart About us Our expertise Services & Sectors Our portfiolio Transactions We're here to help Contact us